Study to assess the effect of Tezepelumab on the immune response to influenza vaccination in participants with asthma

Trial Identifier: D5180C00031
Sponsor: AstraZeneca
Collaborator:
AMGEN
NCTID:: NCT05062759
Start Date: August 2021
Primary Completion Date: March 2022
Study Completion Date: July 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation

Trial Locations

Country Location
US, AZ Tempe, AZ, US, 85283
US, CA Bakersfield, CA, US, 93301
US, CA Huntington Beach, CA, US, 92647
US, CA Long Beach, CA, US, 90806
US, CA Riverside, CA, US, 92506
US, FL Miami, FL, US, 33133
US, MD Annapolis, MD, US, 21401
US, MO Columbia, MO, US, 65203
US, MO Rolla, MO, US, 65401
US, NC Charlotte, NC, US, 28226
US, NE Grand Island, NE, US, 68803
US, NJ Northfield, NJ, US, 08225
US, NJ West Berlin, NJ, US, 08091
US, OH Dayton, OH, US, 45406
US, OH Toledo, OH, US, 43617
US, OK Edmond, OK, US, 73034
US, OK Oklahoma City, OK, US, 73120
US, TX Baytown, TX, US, 77521
US, TX Dallas, TX, US, 75225
US, TX Houston, TX, US, 77099
US, TX San Antonio, TX, US, 78229
US, TX Tyler, TX, US, 75708
US, TX Waco, TX, US, 76712
US, UT Salt Lake City, UT, US, 84107
US, WI Milwaukee, WI, US, 53228